首页 > 最新文献

Pediatric Investigation最新文献

英文 中文
Current situation and prospect for the diagnosis and treatment of pediatric critical rare diseases in China. 中国儿科危重罕见病诊治现状与展望。
IF 1.9 4区 医学 Q2 PEDIATRICS Pub Date : 2024-02-21 eCollection Date: 2024-03-01 DOI: 10.1002/ped4.12419
Yingchao Liu, Suyun Qian

The onset of critical rare diseases (RDs) in children is rapid and dangerous, accompanied by a high mortality rate, which brings a heavy burden to both families and society. Multiple malformations, neuromuscular diseases, metabolic diseases, and heart diseases are the most common types of RDs in children of China, often manifesting with multiple organ dysfunction. At present, the diagnosis and treatment of critical RDs in children face challenges such as prolonged diagnosis time, a high misdiagnosis rate, limited treatment modalities, and a significant disease burden. However, with the progress in genetic testing technology, the establishment of multidisciplinary diagnosis and treatment platforms, and the implementation of relevant RD policies in China, children with critical RDs will received enhanced medical services, experience improved prognoses, and reintegrate into social life.

儿童危重罕见病(RDs)发病急、危害大、死亡率高,给家庭和社会带来沉重负担。多发性畸形、神经肌肉疾病、代谢性疾病和心脏病是我国儿童最常见的罕见病类型,常表现为多器官功能障碍。目前,儿童危重症 RD 的诊断和治疗面临着诊断时间长、误诊率高、治疗手段有限、疾病负担重等挑战。然而,随着我国基因检测技术的进步、多学科诊疗平台的建立以及相关 RD 政策的实施,危重 RD 患儿将获得更好的医疗服务、预后得到改善,并重新融入社会生活。
{"title":"Current situation and prospect for the diagnosis and treatment of pediatric critical rare diseases in China.","authors":"Yingchao Liu, Suyun Qian","doi":"10.1002/ped4.12419","DOIUrl":"10.1002/ped4.12419","url":null,"abstract":"<p><p>The onset of critical rare diseases (RDs) in children is rapid and dangerous, accompanied by a high mortality rate, which brings a heavy burden to both families and society. Multiple malformations, neuromuscular diseases, metabolic diseases, and heart diseases are the most common types of RDs in children of China, often manifesting with multiple organ dysfunction. At present, the diagnosis and treatment of critical RDs in children face challenges such as prolonged diagnosis time, a high misdiagnosis rate, limited treatment modalities, and a significant disease burden. However, with the progress in genetic testing technology, the establishment of multidisciplinary diagnosis and treatment platforms, and the implementation of relevant RD policies in China, children with critical RDs will received enhanced medical services, experience improved prognoses, and reintegrate into social life.</p>","PeriodicalId":19992,"journal":{"name":"Pediatric Investigation","volume":"8 1","pages":"66-71"},"PeriodicalIF":1.9,"publicationDate":"2024-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10951483/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140185166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Spotlight on eltrombopag concentration in pediatric immune thrombocytopenia: A single-center observational study in China. 聚焦艾曲波帕在小儿免疫性血小板减少症中的应用:中国单中心观察性研究。
IF 1.9 4区 医学 Q2 PEDIATRICS Pub Date : 2024-01-29 eCollection Date: 2024-03-01 DOI: 10.1002/ped4.12411
Shuyue Dong, Zhifa Wang, Nan Wang, Jingyao Ma, Jinxi Meng, Yixin Sun, Xiaoling Cheng, Runhui Wu

Importance: Eltrombopag has been recommended for pediatric immune thrombocytopenia (ITP). Response and adverse drug reactions (ADRs) varied widely between individuals, even at the same dose of eltrombopag. The appropriate eltrombopag concentration in ITP has not been reported.

Objective: This study aims to explore the appropriate eltrombopag concentration in pediatric ITP.

Methods: This was a single-center, prospective cohort study. Children diagnosed with refractory persistent/chronic ITP and platelet count < 30×109/L were treated with eltrombopag and followed up for at least 2 months. Concentration was detected by high-performance liquid chromatography-mass spectrometry at least 2 weeks after eltrombopag. The clinical characteristics-concentration, concentration-response, and concentration-ADRs were analyzed.

Results: A total of 30 patients were enrolled, comprising 13 males and 17 females, with a median age of 72 (45‒94) months. The median dose and concentration were 1.39 (1.09‒1.56) mg/kg and 2.70 (2.25‒4.13) mg/L, respectively. Of the enrolled patients, 14 responded to treatment, whereas 16 did not. Additionally, five experienced adverse drug reactions. No linear correlation was observed between eltrombopag concentration and clinical characteristics. The concentration was lower in the response group than in the nonresponse group, but there was no significant difference (t = 0.755, P = 0.457). Patients who experienced ADRs had a higher concentration than those without ADRs (t = 2.538, P = 0.017). The area under the receiver operating characteristic curve of ADRs was 0.78 (95% confidence interval: 0.56‒1.00). Youden's index identified the cutoff point as 4.33 mg/L, with a sensitivity of 88% and a specificity of 60%. Logistic regression analysis demonstrated that a higher platelet count before eltrombopag predicted a favorable response.

Interpretation: Eltrombopag proves efficacious and well-tolerated for treating pediatric ITP. However, prolonged and high-dose administration may increase the likelihood of ADRs. Thus, examining the appropriate eltrombopag concentration assists in directing individualized management of pediatric ITP.

重要性:艾曲波帕已被推荐用于治疗小儿免疫性血小板减少症(ITP)。即使服用相同剂量的艾曲波帕,个体之间的反应和药物不良反应(ADRs)也有很大差异。艾曲波帕在ITP中的适宜浓度尚未见报道:本研究旨在探讨艾曲波帕在小儿ITP中的适宜浓度:这是一项单中心、前瞻性队列研究。被诊断为难治性持续性/慢性 ITP 且血小板计数< 30×109/L 的儿童接受艾曲波帕治疗,并随访至少 2 个月。艾曲波帕治疗至少两周后,用高效液相色谱-质谱法检测血药浓度。分析了临床特征-浓度、浓度-反应和浓度-ADRs:共有 30 名患者入组,其中男性 13 人,女性 17 人,中位年龄为 72(45-94)个月。中位剂量和浓度分别为 1.39(1.09-1.56)毫克/千克和 2.70(2.25-4.13)毫克/升。在登记的患者中,14 人对治疗有反应,16 人没有反应。此外,5 人出现了药物不良反应。艾曲波帕格浓度与临床特征之间没有线性关系。有反应组的浓度低于无反应组,但无显著差异(t = 0.755,P = 0.457)。出现 ADR 的患者的浓度高于无 ADR 的患者(t = 2.538,P = 0.017)。ADRs接收者操作特征曲线下面积为0.78(95%置信区间:0.56-1.00)。尤登指数确定的临界点为 4.33 毫克/升,灵敏度为 88%,特异度为 60%。逻辑回归分析表明,艾曲波帕治疗前血小板计数越高,预示着治疗效果越好:艾曲波帕治疗小儿ITP疗效显著,耐受性良好。然而,长期大剂量用药可能会增加发生不良反应的可能性。因此,研究艾曲波帕的适当浓度有助于指导儿科ITP的个体化治疗。
{"title":"Spotlight on eltrombopag concentration in pediatric immune thrombocytopenia: A single-center observational study in China.","authors":"Shuyue Dong, Zhifa Wang, Nan Wang, Jingyao Ma, Jinxi Meng, Yixin Sun, Xiaoling Cheng, Runhui Wu","doi":"10.1002/ped4.12411","DOIUrl":"10.1002/ped4.12411","url":null,"abstract":"<p><strong>Importance: </strong>Eltrombopag has been recommended for pediatric immune thrombocytopenia (ITP). Response and adverse drug reactions (ADRs) varied widely between individuals, even at the same dose of eltrombopag. The appropriate eltrombopag concentration in ITP has not been reported.</p><p><strong>Objective: </strong>This study aims to explore the appropriate eltrombopag concentration in pediatric ITP.</p><p><strong>Methods: </strong>This was a single-center, prospective cohort study. Children diagnosed with refractory persistent/chronic ITP and platelet count < 30×10<sup>9</sup>/L were treated with eltrombopag and followed up for at least 2 months. Concentration was detected by high-performance liquid chromatography-mass spectrometry at least 2 weeks after eltrombopag. The clinical characteristics-concentration, concentration-response, and concentration-ADRs were analyzed.</p><p><strong>Results: </strong>A total of 30 patients were enrolled, comprising 13 males and 17 females, with a median age of 72 (45‒94) months. The median dose and concentration were 1.39 (1.09‒1.56) mg/kg and 2.70 (2.25‒4.13) mg/L, respectively. Of the enrolled patients, 14 responded to treatment, whereas 16 did not. Additionally, five experienced adverse drug reactions. No linear correlation was observed between eltrombopag concentration and clinical characteristics. The concentration was lower in the response group than in the nonresponse group, but there was no significant difference (<i>t</i> = 0.755, <i>P</i> = 0.457). Patients who experienced ADRs had a higher concentration than those without ADRs (<i>t</i> = 2.538, <i>P</i> = 0.017). The area under the receiver operating characteristic curve of ADRs was 0.78 (95% confidence interval: 0.56‒1.00). Youden's index identified the cutoff point as 4.33 mg/L, with a sensitivity of 88% and a specificity of 60%. Logistic regression analysis demonstrated that a higher platelet count before eltrombopag predicted a favorable response.</p><p><strong>Interpretation: </strong>Eltrombopag proves efficacious and well-tolerated for treating pediatric ITP. However, prolonged and high-dose administration may increase the likelihood of ADRs. Thus, examining the appropriate eltrombopag concentration assists in directing individualized management of pediatric ITP.</p>","PeriodicalId":19992,"journal":{"name":"Pediatric Investigation","volume":"8 1","pages":"44-52"},"PeriodicalIF":1.9,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10951492/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140185168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Coverage and determinants of infant postnatal care in Nigeria: A population-based cross-sectional study. 尼日利亚婴儿产后护理的覆盖面和决定因素:基于人口的横断面研究。
IF 1.9 4区 医学 Q2 PEDIATRICS Pub Date : 2024-01-22 eCollection Date: 2024-03-01 DOI: 10.1002/ped4.12412
Bolaji Emmanuel Egbewale, Olusola Oyedeji, Jesse Bump, Christopher Robert Sudfeld

Importance: In 2019, Nigeria had the largest number of under-5 child deaths globally and many of these deaths occurred within the first week of life. The World Health Organization recommends infant postnatal care (PNC) attendance to support newborn survival; however, utilization of PNC is known to be low in many contexts.

Objective: This study examined coverage and individual-level determinants of infant PNC attendance in Nigeria.

Methods: Nigeria Demographic Health Survey (NDHS) 2018 data were used to evaluate infant PNC coverage and determinants. Infant PNC was defined as receipt of care within 2 days of birth. Children delivered up to 2 years before the 2018 NDHS were included. We examined predictors of infant PNC with modified Poisson regression models to estimate relative risks (RRs).

Results: The national coverage of infant PNC was 37.3% (95% confidence interval [CI]: 35.8%-38.7%). Significant heterogeneity in PNC attendance existed at state and regional levels. Facility delivery was strongly associated with the uptake of PNC (RR: 6.07; 95% CI: 5.60-6.58). Greater maternal education, maternal employment, urban residence, female head of household, and greater wealth were also associated with an increased likelihood of PNC visits.

Interpretation: The uptake of infant PNC is low and interventions are urgently needed to promote equity in access and increase demand for PNC in Nigeria.

重要性:2019 年,尼日利亚是全球 5 岁以下儿童死亡人数最多的国家,其中许多死亡发生在新生儿出生后的第一周。世界卫生组织建议参加婴儿产后护理(PNC)以提高新生儿存活率;然而,众所周知,在许多情况下,婴儿产后护理的利用率很低:本研究探讨了尼日利亚婴儿产后护理的覆盖率和个人层面的决定因素:尼日利亚人口健康调查(NDHS)2018 年的数据用于评估婴儿 PNC 的覆盖率和决定因素。婴儿 PNC 的定义是在出生后 2 天内接受护理。在 2018 年 NDHS 之前 2 年分娩的婴儿也包括在内。我们用修正的泊松回归模型来估算相对风险系数(RRs),从而研究了婴儿PNC的预测因素:全国婴儿PNC覆盖率为37.3%(95%置信区间[CI]:35.8%-38.7%)。在州和地区层面,参加 PNC 的情况存在显著的异质性。设施接生与接受 PNC 密切相关(RR:6.07;95% CI:5.60-6.58)。孕产妇受教育程度越高、就业率越高、居住在城市、户主为女性以及财富越多,接受 PNC 检查的可能性也就越大:婴儿接受新生儿护理的比例较低,因此迫切需要采取干预措施,以促进尼日利亚新生儿护理的公平性并增加对新生儿护理的需求。
{"title":"Coverage and determinants of infant postnatal care in Nigeria: A population-based cross-sectional study.","authors":"Bolaji Emmanuel Egbewale, Olusola Oyedeji, Jesse Bump, Christopher Robert Sudfeld","doi":"10.1002/ped4.12412","DOIUrl":"10.1002/ped4.12412","url":null,"abstract":"<p><strong>Importance: </strong>In 2019, Nigeria had the largest number of under-5 child deaths globally and many of these deaths occurred within the first week of life. The World Health Organization recommends infant postnatal care (PNC) attendance to support newborn survival; however, utilization of PNC is known to be low in many contexts.</p><p><strong>Objective: </strong>This study examined coverage and individual-level determinants of infant PNC attendance in Nigeria.</p><p><strong>Methods: </strong>Nigeria Demographic Health Survey (NDHS) 2018 data were used to evaluate infant PNC coverage and determinants. Infant PNC was defined as receipt of care within 2 days of birth. Children delivered up to 2 years before the 2018 NDHS were included. We examined predictors of infant PNC with modified Poisson regression models to estimate relative risks (RRs).</p><p><strong>Results: </strong>The national coverage of infant PNC was 37.3% (95% confidence interval [CI]: 35.8%-38.7%). Significant heterogeneity in PNC attendance existed at state and regional levels. Facility delivery was strongly associated with the uptake of PNC (RR: 6.07; 95% CI: 5.60-6.58). Greater maternal education, maternal employment, urban residence, female head of household, and greater wealth were also associated with an increased likelihood of PNC visits.</p><p><strong>Interpretation: </strong>The uptake of infant PNC is low and interventions are urgently needed to promote equity in access and increase demand for PNC in Nigeria.</p>","PeriodicalId":19992,"journal":{"name":"Pediatric Investigation","volume":"8 1","pages":"27-36"},"PeriodicalIF":1.9,"publicationDate":"2024-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10951556/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140185165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnose and treatment for Type D congenital esophageal atresia with tracheoesophageal fistula D 型先天性食管闭锁伴气管食管瘘的诊断和治疗
IF 2.2 4区 医学 Q2 PEDIATRICS Pub Date : 2024-01-07 DOI: 10.1002/ped4.12410
Dingding Wang, Yong Zhao, Yanan Zhang, K. Hua, Yichao Gu, Shuangshuang Li, Junmin Liao, Shen Yang, Ting Yang, Jiawei Zhao, Jinshi Huang
Type D esophageal atresia (EA) with tracheoesophageal fistula (TEF) is characterized by EA with both proximal and distal TEFs. It is a rare congenital anomaly with a very low incidence.To investigate diagnostic and treatment strategies for this rare condition.We retrospectively reviewed the clinicopathological features of patients with EA/TEF treated at our institution between January 2007 and September 2021.Among 386 patients with EA/TEF, 14 (3.6%) had type D EA/TEF. Only two patients were diagnosed with proximal TEF preoperatively. Seven patients were diagnosed intraoperatively. Five patients were missed for diagnosis during the initial surgery but was later confirmed by bronchoscopy. During the neonatal period, seven patients underwent a one‐stage repair of proximal and distal TEF via thoracoscopy or thoracotomy. Due to missed diagnosis and other reasons, the other 7 patients underwent two‐stage surgery for repair of the proximal TEF, including cervical incision and thoracoscopy. Ten of the 14 patients experienced postoperative complications including anastomotic leakage, pneumothorax, esophageal stricture, and recurrence. Patients who underwent one‐stage repair of distal and proximal TEF during the neonatal period showed a higher incidence of anastomotic leak (4/7). In contrast, only one of seven patients with two‐stage repair of the proximal TEF developed an anastomotic leak.Type D EA/TEF is a rare condition, and proximal TEFs are easily missed. Bronchoscopy may aim to diagnose and determine the correct surgical approach. A cervical approach may be more suitable for repairing the proximal TEF.
D型食管闭锁(EA)伴气管食管瘘(TEF)的特点是EA伴有近端和远端TEF。我们回顾性分析了2007年1月至2021年9月期间在我院接受治疗的EA/TEF患者的临床病理特征。在386例EA/TEF患者中,14例(3.6%)为D型EA/TEF。只有两名患者在术前被诊断为近端 TEF。七名患者在术中确诊。有 5 名患者在初次手术中漏诊,但后来通过支气管镜检查确诊。在新生儿期,7 名患者通过胸腔镜或开胸手术对 TEF 近端和远端进行了一期修复。由于漏诊和其他原因,另外 7 名患者接受了两阶段的 TEF 近端修复手术,包括颈部切开术和胸腔镜手术。14 名患者中有 10 名出现了术后并发症,包括吻合口漏、气胸、食管狭窄和复发。在新生儿期接受 TEF 远端和近端一期修复的患者吻合口漏的发生率较高(4/7)。相比之下,在对近端 TEF 进行两阶段修复的七名患者中,只有一人出现吻合口漏。支气管镜检查可用于诊断和确定正确的手术方法。颈部入路可能更适合修复近端 TEF。
{"title":"Diagnose and treatment for Type D congenital esophageal atresia with tracheoesophageal fistula","authors":"Dingding Wang, Yong Zhao, Yanan Zhang, K. Hua, Yichao Gu, Shuangshuang Li, Junmin Liao, Shen Yang, Ting Yang, Jiawei Zhao, Jinshi Huang","doi":"10.1002/ped4.12410","DOIUrl":"https://doi.org/10.1002/ped4.12410","url":null,"abstract":"Type D esophageal atresia (EA) with tracheoesophageal fistula (TEF) is characterized by EA with both proximal and distal TEFs. It is a rare congenital anomaly with a very low incidence.To investigate diagnostic and treatment strategies for this rare condition.We retrospectively reviewed the clinicopathological features of patients with EA/TEF treated at our institution between January 2007 and September 2021.Among 386 patients with EA/TEF, 14 (3.6%) had type D EA/TEF. Only two patients were diagnosed with proximal TEF preoperatively. Seven patients were diagnosed intraoperatively. Five patients were missed for diagnosis during the initial surgery but was later confirmed by bronchoscopy. During the neonatal period, seven patients underwent a one‐stage repair of proximal and distal TEF via thoracoscopy or thoracotomy. Due to missed diagnosis and other reasons, the other 7 patients underwent two‐stage surgery for repair of the proximal TEF, including cervical incision and thoracoscopy. Ten of the 14 patients experienced postoperative complications including anastomotic leakage, pneumothorax, esophageal stricture, and recurrence. Patients who underwent one‐stage repair of distal and proximal TEF during the neonatal period showed a higher incidence of anastomotic leak (4/7). In contrast, only one of seven patients with two‐stage repair of the proximal TEF developed an anastomotic leak.Type D EA/TEF is a rare condition, and proximal TEFs are easily missed. Bronchoscopy may aim to diagnose and determine the correct surgical approach. A cervical approach may be more suitable for repairing the proximal TEF.","PeriodicalId":19992,"journal":{"name":"Pediatric Investigation","volume":"23 11","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139448761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent landscape and trends for industry‐sponsored pediatric clinical trials in China from 2013 to 2022 2013-2022年中国行业资助儿科临床试验的最新情况和趋势
IF 2.2 4区 医学 Q2 PEDIATRICS Pub Date : 2024-01-03 DOI: 10.1002/ped4.12409
Chang Liu, Yi Liu, Ling Ou, Yuenan Qi, Jianmin Zhang
Pediatric medication is a challenging issue globally. Promoting trials of medications for children and implementing measures to encourage innovation for addressing unmet medical and health needs are important.To explore the recent landscape of pediatric clinical trials of new investigational drugs conducted by pharmaceutical enterprises in China from 2013 to 2022 to provide insight into pediatric drug development in the pharmaceutical industry and regulatory policy formulation.We performed a cross‐sectional observational investigation of pediatric clinical trials registered from January 1, 2013, to December 31, 2022, on the Registration and Information Disclosure Platform for Drug Clinical Trials, the official registration platform established in 2013 for trials of new investigational drugs initiated by biopharmaceutical enterprises. Trials that included pediatric participants (under 18 years old) were retrieved, and their relevant characteristics were extracted and analyzed.In total, 895 pediatric clinical trials were collected, accounting for 5.1% of the total registered clinical trials initiated prior to January 1, 2023. The overall average annual growth rate for the number of pediatric clinical trials was 12% (P < 0.001). Phase III trials accounted for the highest proportion (49.1%, 439). Of the 895 trials included, 736 (82.2%) were domestic trials, and 159 (17.8%) were international multicenter trials. In terms of tested drugs, investigations of biological products accounted for the largest proportion of trials (67.4%, 603). Among pediatric clinical trials, studies of vaccines accounted for the largest proportion of trials (41.0%, 367), followed by trials for rare diseases (17.2%, 154). Furthermore, geographical distribution analysis revealed that the largest and smallest numbers of trials were conducted in North China (35.7%, 320) and Northeast China (0.8%, 7), respectively.The growth trends for industry‐sponsored clinical trials involving children illustrate the progress and increasing capability of pediatric drug development achieved in China since 2013. Current challenges and potential areas of focus for policymakers and stakeholders include investigating orphan drugs for rare diseases according to the unique epidemiological characteristics of Chinese children, expanding the scope of pediatric clinical trials, and improving the uneven geographical distribution of leading research centers.
儿科用药是一个具有挑战性的全球性问题。为了探索2013年至2022年中国制药企业开展新药临床试验的最新情况,为制药行业儿科药物开发和监管政策制定提供见解。我们对2013年1月1日至2022年12月31日期间在 "药物临床试验注册与信息公开平台 "上注册的儿科临床试验进行了横断面观察调查,该平台于2013年建立,是生物制药企业开展新药临床试验的官方注册平台。共收集到 895 项儿科临床试验,占 2023 年 1 月 1 日前启动的注册临床试验总数的 5.1%。儿科临床试验数量的总体年均增长率为12%(P < 0.001)。III期试验所占比例最高(49.1%,439项)。在纳入的895项试验中,736项(82.2%)为国内试验,159项(17.8%)为国际多中心试验。从试验药物来看,生物制品的研究占比最高(67.4%,603 项)。在儿科临床试验中,疫苗研究占的比例最大(41.0%,367 例),其次是罕见病试验(17.2%,154 例)。行业资助的儿童临床试验的增长趋势表明,自 2013 年以来,中国儿科药物研发取得了长足进步,能力不断增强。目前,政策制定者和利益相关者面临的挑战和潜在的重点领域包括:根据中国儿童独特的流行病学特征研究罕见病孤儿药,扩大儿科临床试验的范围,以及改善领先研究中心地理分布不均衡的状况。
{"title":"Recent landscape and trends for industry‐sponsored pediatric clinical trials in China from 2013 to 2022","authors":"Chang Liu, Yi Liu, Ling Ou, Yuenan Qi, Jianmin Zhang","doi":"10.1002/ped4.12409","DOIUrl":"https://doi.org/10.1002/ped4.12409","url":null,"abstract":"Pediatric medication is a challenging issue globally. Promoting trials of medications for children and implementing measures to encourage innovation for addressing unmet medical and health needs are important.To explore the recent landscape of pediatric clinical trials of new investigational drugs conducted by pharmaceutical enterprises in China from 2013 to 2022 to provide insight into pediatric drug development in the pharmaceutical industry and regulatory policy formulation.We performed a cross‐sectional observational investigation of pediatric clinical trials registered from January 1, 2013, to December 31, 2022, on the Registration and Information Disclosure Platform for Drug Clinical Trials, the official registration platform established in 2013 for trials of new investigational drugs initiated by biopharmaceutical enterprises. Trials that included pediatric participants (under 18 years old) were retrieved, and their relevant characteristics were extracted and analyzed.In total, 895 pediatric clinical trials were collected, accounting for 5.1% of the total registered clinical trials initiated prior to January 1, 2023. The overall average annual growth rate for the number of pediatric clinical trials was 12% (P < 0.001). Phase III trials accounted for the highest proportion (49.1%, 439). Of the 895 trials included, 736 (82.2%) were domestic trials, and 159 (17.8%) were international multicenter trials. In terms of tested drugs, investigations of biological products accounted for the largest proportion of trials (67.4%, 603). Among pediatric clinical trials, studies of vaccines accounted for the largest proportion of trials (41.0%, 367), followed by trials for rare diseases (17.2%, 154). Furthermore, geographical distribution analysis revealed that the largest and smallest numbers of trials were conducted in North China (35.7%, 320) and Northeast China (0.8%, 7), respectively.The growth trends for industry‐sponsored clinical trials involving children illustrate the progress and increasing capability of pediatric drug development achieved in China since 2013. Current challenges and potential areas of focus for policymakers and stakeholders include investigating orphan drugs for rare diseases according to the unique epidemiological characteristics of Chinese children, expanding the scope of pediatric clinical trials, and improving the uneven geographical distribution of leading research centers.","PeriodicalId":19992,"journal":{"name":"Pediatric Investigation","volume":"4 16","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139389596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The clinical characteristics and risk factors for necrotizing soft tissue infection in children 儿童坏死性软组织感染的临床特征和风险因素
IF 2.2 4区 医学 Q2 PEDIATRICS Pub Date : 2023-12-04 DOI: 10.1002/ped4.12408
Jing Liu, Jigang Chen, Yanni Wang, H. Qi, Jing Yu
Necrotizing soft tissue infection (NSTI) is a serious infectious disease. However, the early clinical manifestations and indicators of NSTI in children are still unclear.The purpose of this study was to analyze the clinical characteristics and risk factors of NSTI in pediatric patients.A total of 127 children with skin and soft tissue infection (SSTI) were treated at our hospital and divided into two groups: the NSTI group and the non‐NSTI group, based on their discharge diagnosis from January 2011 to December 2022. Then, we collected and analyzed the clinical characteristics and risk factors of all patients, including sex and age, disease inducement, admission temperature, local skin manifestations, infection site, the presence of sepsis, bacterial culture, and laboratory indicators.In our study, there was a statistical difference in the age distribution and disease inducement between NSTI and non‐NSTI groups. The occurrence of local skin manifestations (blisters/bullae and ecchymosis) and the presence of sepsis significantly increased in the NSTI group compared to the non‐NSTI group. Additionally, only the platelet count on laboratory tests was statistically different between the NSTI and non‐NSTI groups. Finally, the logistic regression analysis suggested that local skin manifestations such as blisters/bullae, and ecchymosis, as well as the presence of sepsis, were identified as risk factors for NSTI.Children with SSTI and skin manifestations such as blisters/bullae, ecchymosis, and the presence of sepsis are at a higher risk of developing NSTI. These symptoms serve as useful indicators for early detection of NSTI.
坏死性软组织感染(NSTI)是一种严重的传染病。然而,儿童NSTI的早期临床表现和指标尚不清楚。本研究旨在分析小儿NSTI的临床特点及危险因素。选取我院2011年1月至2022年12月收治的127例皮肤软组织感染(SSTI)患儿,根据出院诊断分为皮肤软组织感染组和非皮肤软组织感染组。然后收集并分析所有患者的临床特征及危险因素,包括性别、年龄、疾病诱因、入院温度、局部皮肤表现、感染部位、是否存在败血症、细菌培养、实验室指标等。在我们的研究中,NSTI组和非NSTI组在年龄分布和疾病诱因方面存在统计学差异。与非NSTI组相比,NSTI组的局部皮肤表现(水泡/大疱和瘀斑)和败血症的发生率显著增加。此外,只有实验室检测的血小板计数在NSTI组和非NSTI组之间有统计学差异。最后,logistic回归分析表明,局部皮肤表现如水泡/大疱、瘀斑以及脓毒症的存在是NSTI的危险因素。患有SSTI和皮肤表现(如水泡/大疱、瘀斑和败血症)的儿童发生NSTI的风险更高。这些症状是早期发现NSTI的有用指标。
{"title":"The clinical characteristics and risk factors for necrotizing soft tissue infection in children","authors":"Jing Liu, Jigang Chen, Yanni Wang, H. Qi, Jing Yu","doi":"10.1002/ped4.12408","DOIUrl":"https://doi.org/10.1002/ped4.12408","url":null,"abstract":"Necrotizing soft tissue infection (NSTI) is a serious infectious disease. However, the early clinical manifestations and indicators of NSTI in children are still unclear.The purpose of this study was to analyze the clinical characteristics and risk factors of NSTI in pediatric patients.A total of 127 children with skin and soft tissue infection (SSTI) were treated at our hospital and divided into two groups: the NSTI group and the non‐NSTI group, based on their discharge diagnosis from January 2011 to December 2022. Then, we collected and analyzed the clinical characteristics and risk factors of all patients, including sex and age, disease inducement, admission temperature, local skin manifestations, infection site, the presence of sepsis, bacterial culture, and laboratory indicators.In our study, there was a statistical difference in the age distribution and disease inducement between NSTI and non‐NSTI groups. The occurrence of local skin manifestations (blisters/bullae and ecchymosis) and the presence of sepsis significantly increased in the NSTI group compared to the non‐NSTI group. Additionally, only the platelet count on laboratory tests was statistically different between the NSTI and non‐NSTI groups. Finally, the logistic regression analysis suggested that local skin manifestations such as blisters/bullae, and ecchymosis, as well as the presence of sepsis, were identified as risk factors for NSTI.Children with SSTI and skin manifestations such as blisters/bullae, ecchymosis, and the presence of sepsis are at a higher risk of developing NSTI. These symptoms serve as useful indicators for early detection of NSTI.","PeriodicalId":19992,"journal":{"name":"Pediatric Investigation","volume":"2 20","pages":""},"PeriodicalIF":2.2,"publicationDate":"2023-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138603898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Will artificial intelligence widen the therapeutic gap between children and adults? 人工智能会扩大儿童与成人之间的治疗差距吗?
IF 2.2 4区 医学 Q2 PEDIATRICS Pub Date : 2023-12-01 DOI: 10.1002/ped4.12407
Matthew R. Nagy, Bryan Sisk, Albert Lai, Eric Kodish
{"title":"Will artificial intelligence widen the therapeutic gap between children and adults?","authors":"Matthew R. Nagy, Bryan Sisk, Albert Lai, Eric Kodish","doi":"10.1002/ped4.12407","DOIUrl":"https://doi.org/10.1002/ped4.12407","url":null,"abstract":"","PeriodicalId":19992,"journal":{"name":"Pediatric Investigation","volume":" 5","pages":""},"PeriodicalIF":2.2,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138617240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multilevel omics for the discovery of biomarkers in pediatric sepsis. 多层次组学用于发现儿童败血症的生物标志物。
IF 1.9 4区 医学 Q2 PEDIATRICS Pub Date : 2023-11-21 eCollection Date: 2023-12-01 DOI: 10.1002/ped4.12405
Xinyu Wang, Rubo Li, Suyun Qian, Dan Yu

Severe sepsis causes organ dysfunction and continues to be the leading reason for pediatric death worldwide. Early recognition of sepsis could substantially promote precision treatment and reduce the risk of pediatric death. The host cellular response to infection during sepsis between adults and pediatrics could be significantly different. A growing body of studies focused on finding markers in pediatric sepsis in recent years using multi-omics approaches. This narrative review summarized the progress in studying pediatric sepsis biomarkers from genome, transcript, protein, and metabolite levels according to the omics technique that has been applied for biomarker screening. It is most likely not a single biomarker could work for precision diagnosis of sepsis, but a panel of markers and probably a combination of markers detected at multi-levels. Importantly, we emphasize the importance of group distinction of infectious agents in sepsis patients for biomarker identification, because the host response to infection of bacteria, virus, or fungus could be substantially different and thus the results of biomarker screening. Further studies on the investigation of sepsis biomarkers that were caused by a specific group of infectious agents should be encouraged in the future, which will better improve the clinical execution of personalized medicine for pediatric sepsis.

严重败血症导致器官功能障碍,并继续成为全球儿童死亡的主要原因。早期识别脓毒症可以大大促进精确治疗,降低儿童死亡的风险。在成人和儿科败血症期间,宿主细胞对感染的反应可能有显著差异。近年来,越来越多的研究集中在使用多组学方法寻找儿童败血症的标志物。本文综述了应用组学技术筛选儿童败血症生物标志物的研究进展,包括基因组、转录物、蛋白质和代谢物水平。很可能不是单一的生物标记物可以用于败血症的精确诊断,而是一组标记物,可能是在多个水平上检测到的标记物的组合。重要的是,我们强调了脓毒症患者感染因子群体区分对生物标志物鉴定的重要性,因为宿主对细菌、病毒或真菌感染的反应可能存在本质差异,因此生物标志物筛选的结果也可能存在本质差异。未来应鼓励对特定感染因子引起的脓毒症生物标志物的进一步研究,这将更好地改善儿科脓毒症个体化治疗的临床执行。
{"title":"Multilevel omics for the discovery of biomarkers in pediatric sepsis.","authors":"Xinyu Wang, Rubo Li, Suyun Qian, Dan Yu","doi":"10.1002/ped4.12405","DOIUrl":"10.1002/ped4.12405","url":null,"abstract":"<p><p>Severe sepsis causes organ dysfunction and continues to be the leading reason for pediatric death worldwide. Early recognition of sepsis could substantially promote precision treatment and reduce the risk of pediatric death. The host cellular response to infection during sepsis between adults and pediatrics could be significantly different. A growing body of studies focused on finding markers in pediatric sepsis in recent years using multi-omics approaches. This narrative review summarized the progress in studying pediatric sepsis biomarkers from genome, transcript, protein, and metabolite levels according to the omics technique that has been applied for biomarker screening. It is most likely not a single biomarker could work for precision diagnosis of sepsis, but a panel of markers and probably a combination of markers detected at multi-levels. Importantly, we emphasize the importance of group distinction of infectious agents in sepsis patients for biomarker identification, because the host response to infection of bacteria, virus, or fungus could be substantially different and thus the results of biomarker screening. Further studies on the investigation of sepsis biomarkers that were caused by a specific group of infectious agents should be encouraged in the future, which will better improve the clinical execution of personalized medicine for pediatric sepsis.</p>","PeriodicalId":19992,"journal":{"name":"Pediatric Investigation","volume":"7 4","pages":"277-289"},"PeriodicalIF":1.9,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693667/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138482849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recurrent infection triggered encephalopathy syndrome in a pediatric patient with RANBP2 mutation and severe acute respiratory syndrome coronavirus 2 infection. 1例伴有RANBP2突变和严重急性呼吸综合征冠状病毒2感染的儿科患者反复感染引发脑病综合征
IF 1.9 4区 医学 Q2 PEDIATRICS Pub Date : 2023-11-19 eCollection Date: 2023-12-01 DOI: 10.1002/ped4.12406
Jiaqi Li, Feng Huo, Shuo Wang, Yimu Fan, Jie Wu, Zhezhe Zhang, Shuangjun Liu, Quan Wang

Introduction: Acute necrotizing encephalopathy (ANE), a fatal subtype of infection-triggered encephalopathy syndrome (ITES), can be triggered by many systemic infections. RANBP2 gene mutations were associated with recurrent ANE.

Case presentation: Here we report a 1-year-old girl with recurrent ITES and RANBP2 mutation. She was diagnosed with influenza-associated encephalopathy and made a full recovery on the first episode. After severe acute respiratory syndrome coronavirus 2 infection, the patient presented with seizures and deteriorating mental status. Brain magnetic resonance imaging revealed necrotic lesions in bilateral thalami and pons. Methylprednisolone, immunoglobulin, and interleukin 6 inhibitors were administered. Her consciousness level was improved at discharge. Nineteen cases of 2019 coronavirus disease-related ANE have been reported, of which 22.2% of patients died and 61.1% had neurologic disabilities. RANBP2 gene mutation was found in five patients, two of whom developed recurrent ITES.

Conclusion: Patients with RANBP2 mutations are at risk for recurrent ITES, may develop ANE, and have a poor prognosis after relapse.

急性坏死性脑病(ANE)是感染引发脑病综合征(ITES)的一种致命亚型,可由许多全身性感染引发。RANBP2基因突变与复发性ANE相关。病例介绍:在这里我们报告一个1岁的女孩复发性ITES和RANBP2突变。她被诊断为流感相关脑病,并在首次发作时完全康复。患者感染严重急性呼吸综合征冠状病毒2型后出现癫痫发作,精神状态恶化。脑磁共振成像显示双侧丘脑和脑桥坏死病变。给予甲基强的松龙、免疫球蛋白和白细胞介素6抑制剂。出院时她的意识水平有所提高。报告了19例与2019冠状病毒病相关的ANE,其中22.2%的患者死亡,61.1%患有神经功能障碍。5例患者发现RANBP2基因突变,其中2例复发性ITES。结论:RANBP2突变患者有复发性ITES的风险,可能发展为ANE,复发后预后较差。
{"title":"Recurrent infection triggered encephalopathy syndrome in a pediatric patient with <i>RANBP2</i> mutation and severe acute respiratory syndrome coronavirus 2 infection.","authors":"Jiaqi Li, Feng Huo, Shuo Wang, Yimu Fan, Jie Wu, Zhezhe Zhang, Shuangjun Liu, Quan Wang","doi":"10.1002/ped4.12406","DOIUrl":"10.1002/ped4.12406","url":null,"abstract":"<p><strong>Introduction: </strong>Acute necrotizing encephalopathy (ANE), a fatal subtype of infection-triggered encephalopathy syndrome (ITES), can be triggered by many systemic infections. <i>RANBP2</i> gene mutations were associated with recurrent ANE.</p><p><strong>Case presentation: </strong>Here we report a 1-year-old girl with recurrent ITES and <i>RANBP2</i> mutation. She was diagnosed with influenza-associated encephalopathy and made a full recovery on the first episode. After severe acute respiratory syndrome coronavirus 2 infection, the patient presented with seizures and deteriorating mental status. Brain magnetic resonance imaging revealed necrotic lesions in bilateral thalami and pons. Methylprednisolone, immunoglobulin, and interleukin 6 inhibitors were administered. Her consciousness level was improved at discharge. Nineteen cases of 2019 coronavirus disease-related ANE have been reported, of which 22.2% of patients died and 61.1% had neurologic disabilities. <i>RANBP2</i> gene mutation was found in five patients, two of whom developed recurrent ITES.</p><p><strong>Conclusion: </strong>Patients with <i>RANBP2</i> mutations are at risk for recurrent ITES, may develop ANE, and have a poor prognosis after relapse.</p>","PeriodicalId":19992,"journal":{"name":"Pediatric Investigation","volume":"7 4","pages":"290-296"},"PeriodicalIF":1.9,"publicationDate":"2023-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693665/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138482850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A narrative review on the role of genetics in children with acute recurrent pancreatitis and chronic pancreatitis 关于遗传学在儿童急性复发性胰腺炎和慢性胰腺炎中的作用的叙述综述
4区 医学 Q2 PEDIATRICS Pub Date : 2023-10-21 DOI: 10.1002/ped4.12404
Bo Yu, Yi Yu, Xinqiong Wang, Chundi Xu, Yuan Xiao
ABSTRACT The incidence of pancreatitis in children has increased over the past two decades. With advances in molecular biological techniques and clinical research, genetic variations have emerged as a pivotal etiological factor in pediatric pancreatitis. This review aims to summarize recent clinical research advancements in understanding pediatric pancreatitis caused by various gene mutations. As of the year 2020, researchers had identified 12 genes implicated in the pathogenesis of pancreatitis. These genes primarily contributed to the development of pancreatitis through three mechanisms. Pancreatitis resulting from these gene mutations exhibits several distinct characteristics, including early onset, a heightened risk of developing pancreatic duct stones, rapid disease progression, and a significantly increased risk of pancreatic endocrine and exocrine dysfunction, as well as pancreatic cancer in the future. Genetic sequencing is recommended for children with pancreatitis based on six indications. The sequencing not only assists in the clinical diagnosis but also enhances our understanding of the pathophysiology of pancreatitis.
在过去的二十年中,儿童胰腺炎的发病率有所增加。随着分子生物学技术和临床研究的进步,遗传变异已成为儿童胰腺炎的关键病因。本文综述了近年来各种基因突变引起的小儿胰腺炎的临床研究进展。截至2020年,研究人员已经确定了12个与胰腺炎发病机制有关的基因。这些基因主要通过三种机制促进胰腺炎的发展。由这些基因突变引起的胰腺炎表现出几个明显的特征,包括发病早、发生胰管结石的风险增加、疾病进展迅速、胰腺内分泌和外分泌功能障碍的风险显著增加,以及未来发生胰腺癌的风险。根据六个适应症,建议对患有胰腺炎的儿童进行基因测序。测序不仅有助于临床诊断,而且提高了我们对胰腺炎病理生理学的认识。
{"title":"A narrative review on the role of genetics in children with acute recurrent pancreatitis and chronic pancreatitis","authors":"Bo Yu, Yi Yu, Xinqiong Wang, Chundi Xu, Yuan Xiao","doi":"10.1002/ped4.12404","DOIUrl":"https://doi.org/10.1002/ped4.12404","url":null,"abstract":"ABSTRACT The incidence of pancreatitis in children has increased over the past two decades. With advances in molecular biological techniques and clinical research, genetic variations have emerged as a pivotal etiological factor in pediatric pancreatitis. This review aims to summarize recent clinical research advancements in understanding pediatric pancreatitis caused by various gene mutations. As of the year 2020, researchers had identified 12 genes implicated in the pathogenesis of pancreatitis. These genes primarily contributed to the development of pancreatitis through three mechanisms. Pancreatitis resulting from these gene mutations exhibits several distinct characteristics, including early onset, a heightened risk of developing pancreatic duct stones, rapid disease progression, and a significantly increased risk of pancreatic endocrine and exocrine dysfunction, as well as pancreatic cancer in the future. Genetic sequencing is recommended for children with pancreatitis based on six indications. The sequencing not only assists in the clinical diagnosis but also enhances our understanding of the pathophysiology of pancreatitis.","PeriodicalId":19992,"journal":{"name":"Pediatric Investigation","volume":"110 2","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135511017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Pediatric Investigation
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1